Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BDSX Stock Forecast 2026-2027
$7.88
Current Price
$63.04M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to BDSX Price Targets
+407.6%
To High Target of $40.00
+344.2%
To Median Target of $35.00
+153.8%
To Low Target of $20.00
BDSX Price Momentum
-2.5%
1 Week Change
+17.8%
1 Month Change
-65.7%
1 Year Change
+15.9%
Year-to-Date Change
-66.6%
From 52W High of $23.56
+129.1%
From 52W Low of $3.44
📊 TOP ANALYST CALLS
Did BDSX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Biodesix is one of their latest high-conviction picks.
Latest BDSX Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, BDSX has a bullish consensus with a median price target of $35.00 (ranging from $20.00 to $40.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $7.88, the median forecast implies a 344.2% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Kyle Mikson at Canaccord Genuity, suggesting a 153.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BDSX Analyst Ratings
4
Buy
1
Hold
0
Sell
BDSX Price Target Range
Low
$20.00
Average
$35.00
High
$40.00
Current: $7.88
Latest BDSX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BDSX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 19, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $20.00 |
| May 21, 2025 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $2.00 |
| May 14, 2025 | Craig-Hallum | Bill Bonello | Buy | Maintains | $1.50 |
| May 14, 2025 | Lake Street | Thomas Flaten | Buy | Maintains | $2.00 |
| May 14, 2025 | William Blair | Brian Weinstein | Market Perform | Downgrade | $N/A |
| May 14, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $1.50 |
| Apr 29, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $2.50 |
| Sep 16, 2024 | Scotiabank | Sung Ji Nam | Sector Outperform | Initiates | $3.00 |
| Jul 26, 2024 | Craig-Hallum | Bill Bonello | Buy | Initiates | $3.00 |
| May 13, 2024 | TD Cowen | Dan Brennan | Buy | Initiates | $2.80 |
| May 3, 2024 | Lake Street | Buy | Initiates | $3.00 | |
| Mar 4, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Reiterates | $3.50 |
| Dec 7, 2023 | Canaccord Genuity | Kyle Mikson | Buy | Reiterates | $3.50 |
| May 12, 2022 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $5.00 |
| Apr 20, 2022 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Nov 17, 2021 | Morgan Stanley | Tejas Savant | Equal-Weight | Downgrade | $11.00 |
| May 12, 2021 | Morgan Stanley | Overweight | Maintains | $23.00 | |
| Mar 18, 2021 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $25.00 |
| Feb 2, 2021 | Canaccord Genuity | Max Masucci | Buy | Maintains | $31.00 |
| Nov 23, 2020 | Morgan Stanley | Overweight | Initiates | $N/A |
Biodesix Inc. (BDSX) Competitors
The following stocks are similar to Biodesix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biodesix Inc. (BDSX) Financial Data
Biodesix Inc. has a market capitalization of $63.04M with a P/E ratio of -1.2x. The company generates $80.17M in trailing twelve-month revenue with a -49.3% profit margin.
Revenue growth is +19.9% quarter-over-quarter, while maintaining an operating margin of -32.4% and return on equity of -302.6%.
Valuation Metrics
Market Cap
$63.04M
Enterprise Value
$120.47M
P/E Ratio
-1.2x
PEG Ratio
0.1x
Price/Sales
0.8x
Growth & Margins
Revenue Growth (YoY)
+19.9%
Gross Margin
+81.1%
Operating Margin
-32.4%
Net Margin
-49.3%
EPS Growth
+19.9%
Financial Health
Cash/Price Ratio
+26.5%
Current Ratio
1.8x
Debt/Equity
-43.2x
ROE
-302.6%
ROA
-21.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Biodesix Inc. (BDSX) Business Model
About Biodesix Inc.
What They Do
Develops innovative blood-based diagnostics for cancer.
Business Model
Biodesix generates revenue by offering proprietary diagnostic tests that assist healthcare providers and patients in the detection, diagnosis, and monitoring of lung cancer. By providing fast and accurate multi-omics based diagnostic information, the company supports clinical decision-making and helps optimize treatment strategies.
Additional Information
Biodesix is positioned in the growing personalized healthcare sector, focusing on non-invasive testing. Its diagnostic solutions are crucial in guiding therapeutic decisions and advancing new cancer treatments, ultimately aiming to improve patient outcomes and quality of life.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
273
CEO
Mr. Scott Hutton
Country
United States
IPO Year
2020
Website
www.biodesix.comBiodesix Inc. (BDSX) Latest News & Analysis
Latest News
Quick Summary
Q4 2025 revenue is estimated at $28.8M, up 41%. Full-year revenue is projected at $88.5M, a 24% increase. Company reaffirms guidance for positive Adjusted EBITDA in Q4 2025.
Why It Matters
Strong revenue growth and positive EBITDA guidance signal financial health and potential profitability, which may boost investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Biodesix, Inc. will present data on Nodify Lung® tests for early lung cancer diagnosis at NACLC and a new ESR1 assay for breast cancer at SABCS, highlighting advancements in cancer diagnostics.
Why It Matters
Biodesix's presentations on lung cancer and breast cancer diagnostics may enhance its market position, potentially leading to increased revenue and investor interest in its innovative solutions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade
1 month ago
Quick Summary
Analysts project a 325.7% upside for Biodesix (BDSX), supported by a consensus on raised earnings estimates, despite past price target effectiveness being questionable.
Why It Matters
Analysts' price targets suggest significant upside for Biodesix, indicating potential growth. Consensus on rising earnings estimates strengthens the bullish outlook for the stock.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Biodesix, Inc. (BDSX) will hold its Q3 2025 earnings call on November 3, 2025, at 4:30 PM EST, featuring key executives including CEO Scott Hutton and CFO Robin Cowie.
Why It Matters
Biodesix's Q3 earnings call indicates potential financial performance insights and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Q3 2025 revenue reached $21.8 million, up 20% from Q3 2024, with a gross profit margin of 81%. FY2025 revenue guidance raised to $84-86 million. Conference call at 4:30 p.m. ET today.
Why It Matters
Strong revenue growth and improved profit margins signal robust business performance, while raised guidance suggests confidence in future earnings, positively influencing investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Biodesix, Inc. (BDSX) reported a quarterly loss of $1.16 per share, better than the Zacks estimate of $1.60, and improved from a loss of $1.40 per share a year prior.
Why It Matters
Biodesix's smaller-than-expected loss indicates improving financial performance, potentially boosting investor confidence and impacting stock price positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About BDSX Stock
What is Biodesix Inc.'s (BDSX) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Biodesix Inc. (BDSX) has a median price target of $35.00. The highest price target is $40.00 and the lowest is $20.00.
Is BDSX stock a good investment in 2026?
According to current analyst ratings, BDSX has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BDSX stock?
Wall Street analysts predict BDSX stock could reach $35.00 in the next 12 months. This represents a 344.2% increase from the current price of $7.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biodesix Inc.'s business model?
Biodesix generates revenue by offering proprietary diagnostic tests that assist healthcare providers and patients in the detection, diagnosis, and monitoring of lung cancer. By providing fast and accurate multi-omics based diagnostic information, the company supports clinical decision-making and helps optimize treatment strategies.
What is the highest forecasted price for BDSX Biodesix Inc.?
The highest price target for BDSX is $40.00 from at , which represents a 407.6% increase from the current price of $7.88.
What is the lowest forecasted price for BDSX Biodesix Inc.?
The lowest price target for BDSX is $20.00 from Kyle Mikson at Canaccord Genuity, which represents a 153.8% increase from the current price of $7.88.
What is the overall BDSX consensus from analysts for Biodesix Inc.?
The overall analyst consensus for BDSX is bullish. Out of 9 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are BDSX stock price projections?
Stock price projections, including those for Biodesix Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 6:42 AM UTC